Treatment outcomes after intraluminal brachytherapy following definitive chemoradiotherapy in patients with esophageal cancer

• DOI: 10.4103/0973-1482.136623
• Publication Date: 2014-11-03T04:32:56Z
• Authors: Sourjya Banerjee; Krishna Sharan; DonaldJerard Fern...; PU Prakash Saxena; Brijesh Sathian
• Keywords: Chemoradiotherapy

Aims and Objectives: To report the results of treatment with intraluminal brachytherapy (ILRT) after concurrent chemoradiotherapy for esophageal carcinoma respect to disease free survival (DFS), dysphagia interval (DFI), complications treatment. Materials Methods: The study retrospectively analyzed records 26 eligible patients nonmetastatic esophagus treated definitive followed by ILRT between 2008 2011. DFS DFI were estimated factors likely influence them analyzed. Results: Nineteen (73%) males. mean age at presentation was 60 years (range: 47-90 years). All had squamous cell carcinomas. Following treatment, median 12.7 months 0-27 months). Sixteen (61.5%) local control their disease, while one residual completion Other than three who not evaluated recurrent dysphagia, six (23.1%) proven recurrence on follow-up. 13.8 One patient died tracheoesophageal fistula following On statistical analysis, only location tumor prognostically significant, lower third tumors performing worse. probable predictors poor outcome included large volume (> 40 cc), length 6 cm), eccentric location. Conclusion: boost is well tolerated potentially improves outcomes. It might be beneficial in selected carcinoma. Further studies are required identify its role